Our Commitment to Transparency
Janssen recognises that partnerships with healthcare professionals, patients, patient organisations, the health service, policy makers and academia play an important part in developing the most effective therapeutic solutions for unmet medical needs. To ensure successful partnerships, Janssen is fully dedicated to working with all stakeholders based on a partnership of trust and transparency. Our policy is to adhere to strict codes of conduct and internal auditing systems in order to ensure that as a company we are compliant with relevant legal and regulatory requirements.
At Janssen, we are committed to improving transparency in everything we do and wholeheartedly embrace a transparent approach to our partnerships with the healthcare professionals and organisations we work with.
Our Methodology
The information below describes the methodology that Janssen Sciences Ireland UC (Janssen) has applied to disclose the Transfers of Value (ToV) made to Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs), in the submission to the Irish Pharmaceutical Healthcare Association (IPHA) for 2020.
Legitimate Interest
At Janssen, we work in trusted partnerships with patient organisations, and healthcare professionals to help transform lives and reinvent healthcare. Since the 13th of January 2020, Janssen Sciences Ireland UC have introduced a ‘legitimate interest’ model to disclose any payments made to healthcare professionals (HCPs), and healthcare organisations (HCOs) with whom we work.
Our approach to Continuous Professional Development of Healthcare Professionals (HCPs)
At Janssen, we believe that sponsoring and supporting Continuous Professional Development (CPD) programmes (also known as Continuous Medical Education or CME) for HCPs is part of our responsibility for the medicines we develop. By increasing knowledge about diseases and the latest standards of care and treatments, we can help to enhance medical practice as well as improve patient outcomes.
CP-346529 | September 2022